Skip to main content

Table 1 Baseline demographic and disease characteristics of the patients a

From: Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study

 

Not maintained DAS28 (ESR) <2.6 for 24 weeks (n = 146)

Maintained DAS28 (ESR) <2.6 for 24 weeks (n = 69)

Discontinued ADA (n = 51)

P b

Continued ADA (control) (n = 18)

P c

Age, year

61.1 ± 11.6

59.5 ± 11.2

0.3910

64.8 ± 10.4

0.0513

Gender, F:M

127:19

40:11

0.1742

14:4

1.0000

Disease duration, year

9.4 ± 10.3

7.1 ± 9.9

0.0356

6.7 ± 10.1

0.7375

RF, U/mL

137.2 ± 248.5

109.0 ± 143.0

0.5539

283.5 ± 550.5

0.1400

TJC, 0 to 28

8.9 ± 6.7

8.1 ± 6.6

0.4014

7.6 ± 5.4

0.9727

SJC, 0 to 28

7.5 ± 5.5

6.4 ± 5.0

0.1770

6.7 ± 4.5

0.6214

PGA, 0 to 100 mm

53.4 ± 24.8

39.0 ± 24.2

0.0008

47.8 ± 24.7

0.2185

EGA, 0 to 100 mm

39.6 ± 22.7d

31.5 ± 21.3

0.0398

34.7 ± 19.6g

0.4636

CRP, mg/dl

2.89 ± 4.07

2.27 ± 3.71

0.1460

1.61 ± 1.58

0.3817

ESR, mm/hour

51.9 ± 32.4

43.2 ± 33.6

0.0574

45.6 ± 25.0

0.4318

DAS28 (ESR)

5.57 ± 1.27

5.06 ± 1.26

0.0183

5.33 ± 1.25

0.3528

MMP-3, ng/ml

313 ± 363

217 ± 339

0.0301

333 ± 233

0.0005

HAQ, 0 to 3

1.37 ± 0.77e

0.91 ± 0.67

0.0003

1.27 ± 0.51h

0.0295

MTX, mg/wf

8.85 ± 3.11

8.96 ± 2.72

0.8937

9.61 ± 1.97

0.3480

  1. aExcept where indicated otherwise, values are the mean ± SD; bnot maintained DAS28 (ESR) <2.6 for 24 weeks versus maintained DAS28 (ESR) <2.6 for 24 weeks/Discontinued ADA; cmaintained DAS28 (ESR) <2.6 for 24 weeks/Discontinued ADA versus maintained DAS28 (ESR) <2.6 for 24 weeks/Continued ADA (control); dN = 72; eN = 143; fthe mean ± SD were determined including those without concomitant administration of MTX by handling as zero; gN = 10; hN = 16. CPR, C-reactive protein; DAS28, disease activity score; EGA, evaluator’s global assessment of disease activity; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; PGA, patient’s global assessment of disease activity; RF, rheumatoid factor; TJC; tender joint count; SJC, swollen joint count.